https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presentation-canaccord-conference BiopharmaWatch en 2026-07-29T12:16:34.761Z Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston https://www.biopharmawatch.com/news/URGN/urogen-pharma-q2-2026-financial-results BiopharmaWatch en 2026-07-29T12:16:07.891Z UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 https://www.biopharmawatch.com/news/ENLV/enlivex-webinar-capital-strategy-clinical-milestones BiopharmaWatch en 2026-07-29T12:14:02.073Z Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones https://www.biopharmawatch.com/news/TVGN/tevogen-bio-holdings-becomes-tevogen-inc BiopharmaWatch en 2026-07-29T12:13:45.234Z Tevogen Bio Holdings Inc. Becomes Tevogen Inc. https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-announces-150-million-private-placement BiopharmaWatch en 2026-07-29T12:13:29.385Z LB Pharmaceuticals Announces $150 Million Private Placement https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-29T12:13:08.471Z Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-day-2026 BiopharmaWatch en 2026-07-29T12:12:29.630Z NewAmsterdam Pharma to Host Investor Day on August 5, 2026 https://www.biopharmawatch.com/news/A/agilent-research-catalyst-award-eastern-institute-technology BiopharmaWatch en 2026-07-29T12:00:00.000Z Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo https://www.biopharmawatch.com/news/SRRK/scholar-rock-presents-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-29T12:00:00.000Z Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-baylor-scott-white-research-institute BiopharmaWatch en 2026-07-29T12:00:00.000Z Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/MDWD/mediwound-report-second-quarter-2026-results BiopharmaWatch en 2026-07-29T12:00:00.000Z MediWound to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-29T12:00:00.000Z Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MRK/bacterial-vaginosis-merck-manuals-women-partners BiopharmaWatch en 2026-07-29T12:00:00.000Z Bacterial Vaginosis: Merck Manuals Shares What Women and Partners Need to Know https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q2-2026 BiopharmaWatch en 2026-07-29T11:30:00.000Z TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/PCSA/processa-acquisition-vidya-therapeutics-btk-inhibitor BiopharmaWatch en 2026-07-29T11:30:00.000Z PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS https://www.biopharmawatch.com/news/BWAY/brainsway-report-second-quarter-2026-results BiopharmaWatch en 2026-07-29T11:30:00.000Z BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/ACON/aclarion-ceo-shareholder-letter-progress-2026 BiopharmaWatch en 2026-07-29T11:22:04.571Z Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 https://www.biopharmawatch.com/news/CBLL/ceribell-expands-board-directors-west-okeefe BiopharmaWatch en 2026-07-29T11:21:33.258Z Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe https://www.biopharmawatch.com/news/QURE/uniqure-q2-2026-financial-results-update BiopharmaWatch en 2026-07-29T11:18:14.698Z uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update https://www.biopharmawatch.com/news/AXGN/trace-biosciences-axogen-investment-nerve-trace-technology BiopharmaWatch en 2026-07-29T11:10:00.000Z Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology https://www.biopharmawatch.com/news/IONS/ionis-frank-bennett-retirement-announcement BiopharmaWatch en 2026-07-29T11:05:00.000Z Ionis announces Dr. Frank Bennett, chief scientific officer, to retire https://www.biopharmawatch.com/news/AXGN/axogen-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-29T11:05:00.000Z Axogen, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OCGN/ocugen-fda-rmat-designation-ocu410-geographic-atrophy BiopharmaWatch en 2026-07-29T11:01:00.000Z Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-nanopulse-af-study-enrollment-midpoint BiopharmaWatch en 2026-07-29T11:00:00.000Z Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q2-2026-earnings-call BiopharmaWatch en 2026-07-29T11:00:00.000Z National Vision Holdings, Inc. Announces Second Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/IONS/ionis-q2-2026-financial-results-tryngolza-launch BiopharmaWatch en 2026-07-29T11:00:00.000Z Ionis reports second quarter 2026 financial results and highlights progress on key programs https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trial-sil204 BiopharmaWatch en 2026-07-29T11:00:00.000Z Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center https://www.biopharmawatch.com/news/XRTX/xortx-appoints-new-director BiopharmaWatch en 2026-07-29T11:00:00.000Z XORTX Appoints New Director https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-share-issuances-nasdaq-compliance BiopharmaWatch en 2026-07-29T11:00:00.000Z Healthcare Triangle Completes Share Issuances Relating to Legacy M&A Transactions, Strengthening Compliance With Nasdaq's New $5 Million Market Value Listing Standard https://www.biopharmawatch.com/news/CALC/calcimedica-fda-alignment-phase-2b-trial-auxora BiopharmaWatch en 2026-07-29T11:00:00.000Z CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q2-2026-earnings-call-date BiopharmaWatch en 2026-07-29T11:00:00.000Z Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q2-2026-results-conference-call BiopharmaWatch en 2026-07-29T11:00:00.000Z Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-strengthens-patent-portfolio BiopharmaWatch en 2026-07-29T11:00:00.000Z VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates https://www.biopharmawatch.com/news/ADMA/adma-biologics-second-quarter-2026-results BiopharmaWatch en 2026-07-29T11:00:00.000Z ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-first-patient-dosed-phase-3-alloha-2 BiopharmaWatch en 2026-07-29T11:00:00.000Z TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies https://www.biopharmawatch.com/news/AMRN/amarin-q2-2026-financial-results BiopharmaWatch en 2026-07-29T11:00:00.000Z Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence https://www.biopharmawatch.com/news/VTRS/viatris-fda-approval-gwyn-lo-contraceptive-patch BiopharmaWatch en 2026-07-29T10:59:00.000Z Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch https://www.biopharmawatch.com/news/BLCO/bausch-lomb-second-quarter-growth-2026 BiopharmaWatch en 2026-07-29T10:58:00.000Z Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance https://www.biopharmawatch.com/news/BDX/bdx-semaglutide-launch-brazil BiopharmaWatch en 2026-07-29T10:54:00.000Z EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-khindivi-indication-expansion BiopharmaWatch en 2026-07-29T10:50:00.000Z Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution https://www.biopharmawatch.com/news/UTHR/united-therapeutics-advance-outcomes-study-ralinepag BiopharmaWatch en 2026-07-29T10:30:00.000Z United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet https://www.biopharmawatch.com/news/CMPS/compass-pathways-q2-2026-financial-results-announcement BiopharmaWatch en 2026-07-29T10:30:00.000Z Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/BSX/boston-scientific-q2-2026-results BiopharmaWatch en 2026-07-29T10:30:00.000Z Boston Scientific announces results for second quarter 2026 https://www.biopharmawatch.com/news/FTRE/fortrea-reports-q2-2026-results BiopharmaWatch en 2026-07-29T10:30:00.000Z Fortrea Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/MNKD/mannkind-positive-phase-1b-inflo-1-results BiopharmaWatch en 2026-07-29T10:30:00.000Z MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q2-2026-financial-results BiopharmaWatch en 2026-07-29T10:20:00.000Z GE HealthCare reports second quarter 2026 financial results https://www.biopharmawatch.com/news/AVTR/avantor-reports-q2-2026-results BiopharmaWatch en 2026-07-29T10:05:00.000Z Avantor® Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q2-2026-earnings-call BiopharmaWatch en 2026-07-29T10:00:00.000Z Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/IART/integra-lifesciences-q2-2026-financial-results BiopharmaWatch en 2026-07-29T10:00:00.000Z Integra LifeSciences Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MRK/evinova-merck-partnership-clinical-development BiopharmaWatch en 2026-07-29T08:00:00.000Z Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development https://www.biopharmawatch.com/news/ABBV/abbvie-eu-approval-rinvoq-alopecia-areata BiopharmaWatch en 2026-07-29T07:00:00.000Z AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata https://www.biopharmawatch.com/news/ABBV/abbvie-approval-rinvoq-non-segmental-vitiligo BiopharmaWatch en 2026-07-29T07:00:00.000Z AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo https://www.biopharmawatch.com/news/YDES/yd-bio-numia-health-cancer-testing-pilot BiopharmaWatch en 2026-07-29T03:19:28.000Z YD Bio 與 Numia Health 啟動跨境癌症檢測試辦計畫，評估拓展加拿大分子診斷服務之可行性 https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-28T22:00:00.000Z Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets https://www.biopharmawatch.com/news/SEER/seer-stockholders-re-elect-director-nominees-2026 BiopharmaWatch en 2026-07-28T21:40:00.000Z Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting https://www.biopharmawatch.com/news/HCAT/health-catalyst-q2-2026-results-conference-call BiopharmaWatch en 2026-07-28T21:30:00.000Z Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/AMGN/amgen-webcast-2026-q2-financial-results BiopharmaWatch en 2026-07-28T20:45:00.000Z AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS https://www.biopharmawatch.com/news/AGEN/agenus-second-quarter-2026-financial-report-update BiopharmaWatch en 2026-07-28T20:30:00.000Z Agenus to Provide Second Quarter 2026 Financial Report and Development Update https://www.biopharmawatch.com/news/PACS/pacs-group-q2-2026-earnings-release-call BiopharmaWatch en 2026-07-28T20:30:00.000Z PACS Group Schedules Second Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-28T20:30:00.000Z Travere Therapeutics to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TMDX/transmedics-present-canaccord-growth-conference BiopharmaWatch en 2026-07-28T20:29:00.000Z TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/QTI/qt-imaging-holdings-2026-annual-stockholder-meeting-results BiopharmaWatch en 2026-07-28T20:15:00.000Z QT Imaging Holdings Announces Results of 2026 Annual Stockholder Meeting https://www.biopharmawatch.com/news/A/agilent-announces-q3-fy-2026-results BiopharmaWatch en 2026-07-28T20:15:00.000Z Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26 https://www.biopharmawatch.com/news/HAE/martin-madaus-elected-haemonetics-board BiopharmaWatch en 2026-07-28T20:15:00.000Z Martin Madaus Elected to Haemonetics Board of Directors https://www.biopharmawatch.com/news/CHE/chemed-reports-second-quarter-2026-results BiopharmaWatch en 2026-07-28T20:15:00.000Z Chemed Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-nulisa-immune-340-panel-launch BiopharmaWatch en 2026-07-28T20:12:00.000Z Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-q2-2026-results-guidance BiopharmaWatch en 2026-07-28T20:05:00.000Z Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-conference-presentation-2026 BiopharmaWatch en 2026-07-28T20:05:00.000Z Tandem Diabetes Care Announces Upcoming Conference Presentation https://www.biopharmawatch.com/news/NEO/neogenomics-reports-second-quarter-2026-results BiopharmaWatch en 2026-07-28T20:05:00.000Z NeoGenomics Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/TLRY/tilray-brands-record-fiscal-2026-revenue BiopharmaWatch en 2026-07-28T20:05:00.000Z Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness https://www.biopharmawatch.com/news/RARE/ultragenyx-conference-call-q2-2026-results BiopharmaWatch en 2026-07-28T20:05:00.000Z Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/PACB/pacbio-participate-canaccord-genuity-growth-conference BiopharmaWatch en 2026-07-28T20:05:00.000Z PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CBLL/ceribell-participate-canaccord-genuity-conference BiopharmaWatch en 2026-07-28T20:05:00.000Z Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q2-2026-update BiopharmaWatch en 2026-07-28T20:05:00.000Z CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/NPCE/neuropace-fda-guidance-indication-expansion-ige BiopharmaWatch en 2026-07-28T20:01:00.000Z NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q2-results-2026 BiopharmaWatch en 2026-07-28T20:01:00.000Z Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 https://www.biopharmawatch.com/news/DCTH/delcath-systems-participate-canaccord-genuity-conference BiopharmaWatch en 2026-07-28T20:01:00.000Z Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/VSTM/verastem-target-d-203-phase-2-trial-vs-7375 BiopharmaWatch en 2026-07-28T20:01:00.000Z Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/MNKD/mannkind-report-q2-2026-results-conference-call BiopharmaWatch en 2026-07-28T20:01:00.000Z MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026 https://www.biopharmawatch.com/news/OCGN/ocugen-conference-call-august-2026 BiopharmaWatch en 2026-07-28T20:01:00.000Z Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-28T20:01:00.000Z Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/INMD/steel-partners-inmode-shareholders-vote-against BiopharmaWatch en 2026-07-28T20:00:00.000Z Steel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General Meeting https://www.biopharmawatch.com/news/NRC/nrc-health-second-quarter-2026-results BiopharmaWatch en 2026-07-28T20:00:00.000Z NRC Health Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/SEER/radoff-jec-group-improved-proposal-acquire-seer BiopharmaWatch en 2026-07-28T16:47:00.000Z Radoff-JEC Group Submits Further Improved Proposal to Acquire Seer, Inc. https://www.biopharmawatch.com/news/PNTG/pennant-announces-q2-2026-earnings-release-call BiopharmaWatch en 2026-07-28T16:39:00.000Z Pennant Announces Second Quarter 2026 Earnings Release and Call https://www.biopharmawatch.com/news/PHGE/biomx-waterio-zorronet-acquisition-update BiopharmaWatch en 2026-07-28T13:15:00.000Z BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms https://www.biopharmawatch.com/news/XGN/exagen-participate-investor-conference-2026 BiopharmaWatch en 2026-07-28T13:09:05.687Z Exagen Inc. to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/HCAT/midcap-advisors-health-catalyst-acquisition BiopharmaWatch en 2026-07-28T13:03:00.000Z MidCap Advisors Advises Leading Midwest Psychiatric Care Provider in Its Acquisition by Health Catalyst Capital https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-nicotinamide-riboside-aging-analysis BiopharmaWatch en 2026-07-28T12:32:00.000Z Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging https://www.biopharmawatch.com/news/MDLN/dentsply-sirona-expands-medline-sinclair-relationship BiopharmaWatch en 2026-07-28T12:30:00.000Z Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship https://www.biopharmawatch.com/news/ONMD/onemednet-secures-agreement-supply-real-world-data BiopharmaWatch en 2026-07-28T12:30:00.000Z OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-board-appointments BiopharmaWatch en 2026-07-28T12:30:00.000Z Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors https://www.biopharmawatch.com/news/CVRX/cvrx-presents-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-28T12:30:00.000Z CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference https://www.biopharmawatch.com/news/STIM/neuronetics-q2-2026-results-conference-call BiopharmaWatch en 2026-07-28T12:30:00.000Z Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call https://www.biopharmawatch.com/news/QTI/qt-imaging-israeli-health-registration BiopharmaWatch en 2026-07-28T12:30:00.000Z QT Imaging Receives Israeli Ministry of Health Regulatory Registration https://www.biopharmawatch.com/news/ANGO/angiodynamics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-07-28T12:30:00.000Z AngioDynamics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-novel-endoxifen-compounds-breast-cancer BiopharmaWatch en 2026-07-28T12:30:00.000Z Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-appoints-bipin-dalmia-cbo BiopharmaWatch en 2026-07-28T12:30:00.000Z Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q2-2026-financial-results BiopharmaWatch en 2026-07-28T12:13:25.652Z Nautilus Biotechnology Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LEGN/legend-biotech-investor-conference-call-q2-2026 BiopharmaWatch en 2026-07-28T12:06:48.768Z Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results https://www.biopharmawatch.com/news/RIGL/rigel-conference-call-q2-2026-results BiopharmaWatch en 2026-07-28T12:05:00.000Z Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-nasdaq-closing-bell-august-2026 BiopharmaWatch en 2026-07-28T12:01:00.000Z Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-fda-guidance-psychedelic-drug-development BiopharmaWatch en 2026-07-28T12:00:18.000Z Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development https://www.biopharmawatch.com/news/YDES/yd-bio-launches-cancer-testing-pilot-canada BiopharmaWatch en 2026-07-28T12:00:00.000Z YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada https://www.biopharmawatch.com/news/OSCR/oscar-health-2026-investor-day BiopharmaWatch en 2026-07-28T12:00:00.000Z Oscar Health, Inc. to Host 2026 Investor Day https://www.biopharmawatch.com/news/CODX/co-diagnostics-cosara-ebola-test-kits BiopharmaWatch en 2026-07-28T12:00:00.000Z Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies https://www.biopharmawatch.com/news/APYX/apyx-medical-participate-canaccord-growth-conference BiopharmaWatch en 2026-07-28T12:00:00.000Z Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CRBP/corbus-fda-clearance-tempo-1-study-crb-701 BiopharmaWatch en 2026-07-28T12:00:00.000Z Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer https://www.biopharmawatch.com/news/PCRX/pacira-survey-impact-pain-americas-workforce BiopharmaWatch en 2026-07-28T12:00:00.000Z Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce https://www.biopharmawatch.com/news/LAB/standard-biotech-sale-mass-cytometry-illuminas-buyout BiopharmaWatch en 2026-07-28T12:00:00.000Z Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences https://www.biopharmawatch.com/news/ENLV/enlivex-announces-400-million-private-placement BiopharmaWatch en 2026-07-28T12:00:00.000Z Enlivex Announces $400,000,000 Private Placement https://www.biopharmawatch.com/news/PLUR/pluri-advances-commercial-expansion-cellav-uk-registration BiopharmaWatch en 2026-07-28T12:00:00.000Z Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK https://www.biopharmawatch.com/news/AIFF/firefly-next-health-precision-cognitive-health-initiative BiopharmaWatch en 2026-07-28T11:50:00.000Z Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides https://www.biopharmawatch.com/news/CMND/clearmind-medicine-phase-i-ii-trial-success BiopharmaWatch en 2026-07-28T11:47:00.000Z Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial https://www.biopharmawatch.com/news/LTRN/lantern-pharma-ema-phase-1b-2-trial-lp-184 BiopharmaWatch en 2026-07-28T11:45:00.000Z Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-fda-clearance-dyne-302-fshd BiopharmaWatch en 2026-07-28T11:30:00.000Z Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-patent-prevent-metastatic-recurrence BiopharmaWatch en 2026-07-28T11:30:00.000Z Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q2-2026-financial-results-call BiopharmaWatch en 2026-07-28T11:30:00.000Z Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-symposium-2026-sno-asco-conference BiopharmaWatch en 2026-07-28T11:30:00.000Z Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-q2-2026-earnings-call BiopharmaWatch en 2026-07-28T11:30:00.000Z Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-august-conferences BiopharmaWatch en 2026-07-28T11:30:00.000Z Trevi Therapeutics to Participate in Upcoming August Conferences https://www.biopharmawatch.com/news/NSRX/nasus-pharma-ceo-appointment-brendan-ogrady BiopharmaWatch en 2026-07-28T11:30:00.000Z Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth https://www.biopharmawatch.com/news/GH/guardant-health-patrick-dempsey-colorectal-cancer-tribute BiopharmaWatch en 2026-07-28T11:13:00.000Z Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer https://www.biopharmawatch.com/news/ALT/altimmune-positive-results-reclaim-trial-pemvidutide BiopharmaWatch en 2026-07-28T11:06:43.257Z Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-signs-new-customer-agreements BiopharmaWatch en 2026-07-28T11:05:00.000Z Lifecore Biomedical Signs Three New Customer Agreements https://www.biopharmawatch.com/news/INCY/incyte-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ICLR/icon-anthropic-ai-collaboration-clinical-trials BiopharmaWatch en 2026-07-28T11:00:00.000Z ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials https://www.biopharmawatch.com/news/IQV/iqvia-reports-q2-2026-results BiopharmaWatch en 2026-07-28T11:00:00.000Z IQVIA Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/ALKS/alkermes-q2-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Alkermes plc Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OKYO/okyo-pharma-cso-share-purchase BiopharmaWatch en 2026-07-28T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer https://www.biopharmawatch.com/news/NRXS/neuraxis-q2-2026-results-business-update-call BiopharmaWatch en 2026-07-28T11:00:00.000Z NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/RGEN/repligen-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/SNDX/syndax-announces-q2-2026-financial-results-call BiopharmaWatch en 2026-07-28T11:00:00.000Z Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 https://www.biopharmawatch.com/news/AVIR/ateas-bemnifosbuvir-ruzavir-phase-3-trial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-positive-fda-feedback-cln-049 BiopharmaWatch en 2026-07-28T11:00:00.000Z Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML https://www.biopharmawatch.com/news/ARVN/arvinas-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-28T11:00:00.000Z Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-fda-type-a-meeting-minutes BiopharmaWatch en 2026-07-28T11:00:00.000Z Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration https://www.biopharmawatch.com/news/INFU/infusystem-second-quarter-2026-results BiopharmaWatch en 2026-07-28T10:30:00.000Z InfuSystem to Report Second Quarter 2026 Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/PMN/promis-neurosciences-positive-interim-results-pmn310 BiopharmaWatch en 2026-07-28T10:00:00.000Z ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial https://www.biopharmawatch.com/news/OLMA/login-guide-luckyniki-access-issues BiopharmaWatch en 2026-07-28T07:04:03.000Z Guida Al Login Su LuckyNiki E Soluzione Ai Problemi Di Accesso https://www.biopharmawatch.com/news/RDHL/redhill-opaganib-ebola-outbreak-update BiopharmaWatch en 2026-07-28T00:00:00.000Z Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development The number of confirmed Ebola cases and deaths has increased substantially to 3221 cases and 1407 deaths -- Finalization of development next steps... https://www.biopharmawatch.com/news/GLMD/galmed-aramchol-odf-parkinsons-development BiopharmaWatch en 2026-07-28T00:00:00.000Z Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In... https://www.biopharmawatch.com/news/CGON/cg-oncology-bond-003-phase-3-results-lancet-oncology BiopharmaWatch en 2026-07-27T22:45:00.000Z CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology https://www.biopharmawatch.com/news/JNJ/johnson-johnson-talc-litigation-resolution BiopharmaWatch en 2026-07-27T22:31:00.000Z Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation https://www.biopharmawatch.com/news/PMI/picard-medical-syncardia-emperor-heart-technology-embc-2026 BiopharmaWatch en 2026-07-27T21:11:00.000Z Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026 https://www.biopharmawatch.com/news/ATEC/atec-participation-upcoming-investor-conferences BiopharmaWatch en 2026-07-27T20:35:00.000Z ATEC Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AIDX/2020-biolabs-bio-asia-taiwan-strategy BiopharmaWatch en 2026-07-27T20:30:00.000Z 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy https://www.biopharmawatch.com/news/STE/steris-conference-call-fiscal-2027-first-quarter BiopharmaWatch en 2026-07-27T20:30:00.000Z STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026 https://www.biopharmawatch.com/news/UHS/universal-health-services-q2-2026-financial-results BiopharmaWatch en 2026-07-27T20:16:00.000Z UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2026, AND REVISES 2026 FULL YEAR OPERATING RESULTS FORECAST https://www.biopharmawatch.com/news/ACH/accendra-health-leadership-appointments-it-procurement BiopharmaWatch en 2026-07-27T20:05:00.000Z Accendra Health Announces Leadership Appointments in IT and Procurement https://www.biopharmawatch.com/news/OPK/opko-health-q2-2026-results-highlights BiopharmaWatch en 2026-07-27T20:05:00.000Z OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-ipo-2026 BiopharmaWatch en 2026-07-27T20:05:00.000Z Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement https://www.biopharmawatch.com/news/ORGO/organogenesis-affinity-trial-results-venous-leg-ulcers BiopharmaWatch en 2026-07-27T20:05:00.000Z Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers https://www.biopharmawatch.com/news/BNGO/bionano-report-q2-2026-financial-results BiopharmaWatch en 2026-07-27T20:05:00.000Z Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026 https://www.biopharmawatch.com/news/NYXH/nyxoah-q2-2026-financial-results-release BiopharmaWatch en 2026-07-27T20:05:00.000Z Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-webcast-conference-call-q2-2026 BiopharmaWatch en 2026-07-27T20:01:00.000Z Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates https://www.biopharmawatch.com/news/IMCC/im-cannabis-provides-corporate-update BiopharmaWatch en 2026-07-27T20:01:00.000Z IM Cannabis Provides Corporate Update https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q2-2026-results-report BiopharmaWatch en 2026-07-27T20:01:00.000Z Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-cmo BiopharmaWatch en 2026-07-27T20:01:00.000Z Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer https://www.biopharmawatch.com/news/PMN/promis-neurosciences-webinar-precise-ad-trial-data BiopharmaWatch en 2026-07-27T20:00:00.000Z ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease https://www.biopharmawatch.com/news/BTMD/instamed-pharmaceuticals-ceo-appointment-launch-peptide-platform BiopharmaWatch en 2026-07-27T19:35:00.000Z Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform https://www.biopharmawatch.com/news/COSM/cosmos-health-ai-enabled-subscription-platform BiopharmaWatch en 2026-07-27T17:05:00.000Z Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels https://www.biopharmawatch.com/news/OLMA/betfirst-login-troubleshooting-netherlands BiopharmaWatch en 2026-07-27T16:53:33.000Z Betfirst Login Troubleshooting For Users In The Netherlands https://www.biopharmawatch.com/news/NTHI/neonc-appoints-nasim-shomali-board-directors BiopharmaWatch en 2026-07-27T16:21:17.000Z NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors https://www.biopharmawatch.com/news/HCSG/pgp-welcomes-steven-grassa-managing-director BiopharmaWatch en 2026-07-27T16:10:00.000Z PGP Welcomes Steven Grassa as Managing Director to Deepen Healthcare Services Coverage https://www.biopharmawatch.com/news/CAPR/capricor-deramiocel-fda-advisory-meeting-update BiopharmaWatch en 2026-07-27T15:00:00.000Z Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel https://www.biopharmawatch.com/news/AVNS/american-industrial-partners-acquires-avanos-medical BiopharmaWatch en 2026-07-27T13:28:00.000Z American Industrial Partners Completes Acquisition of Avanos Medical, Inc. https://www.biopharmawatch.com/news/ACH/accendra-health-q2-2026-earnings-release-date BiopharmaWatch en 2026-07-27T13:15:00.000Z Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/CRIS/assurecare-curis-partner-rht-funding-infrastructure BiopharmaWatch en 2026-07-27T13:03:00.000Z AssureCare® and CURIS Partner to Ensure RHT Funding Builds Infrastructure That Outlasts the Program https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-ebola-ziare-d-mav-platform BiopharmaWatch en 2026-07-27T13:00:00.000Z Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-07-27T12:32:00.000Z Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/ICCM/icecure-medical-choicestudy-breast-cancer BiopharmaWatch en 2026-07-27T12:32:00.000Z IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-ceo-appointment BiopharmaWatch en 2026-07-27T12:30:00.000Z Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-sonata-hcm-study-enrollment-completed BiopharmaWatch en 2026-07-27T12:30:00.000Z Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) https://www.biopharmawatch.com/news/ENTX/entera-bio-private-placement-275-million BiopharmaWatch en 2026-07-27T12:30:00.000Z Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement